Clinical Trials
9 trialsNCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03696784 2025-12-08
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02663297 2025-05-15
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02658968 2024-01-16
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
Phase 1 Completed
NCT02657447 2019-01-10
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
Phase 1 Withdrawn
NCT01401530 2018-11-23
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 1 Completed
NCT00103779 2014-12-18
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Seagen Inc.
Phase 1 Completed
NCT00655837 2014-12-18
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Seagen Inc.
Phase 1 Completed
NCT00725634 2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1 Completed